Biogen (BIIB) Tops Q3 EPS by 66c, Updates FY Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $196.58 -1.05%
EPS Growth %: -41.3%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 219.4M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -41.3%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 219.4M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.77, $0.66 better than the analyst estimate of $4.11. Revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.
GUIDANCE:
Biogen sees FY2021 EPS of $18.85-$19.35, versus the consensus of $18.61. Biogen sees FY2021 revenue of $10.8-10.9 billion, versus the consensus of $10.76 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Reiterates Buy Rating on Biogen (BIIB)
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
- Kroger meets earnings expectations, revenue tops estimates
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
